Canopus plans to acquire 90% equity of Wuhan Yijiaobao, which is expected to constitute a major asset reorganization

Canopus plans to acquire 90% equity of Wuhan Yijiaobao in cash, which is expected to constitute a significant asset restructuring. Wuhan Yijiaobao focuses on the research, production, and sales of high-end orthopedic and biomedical materials. This transaction aims to integrate industry resources, extend the surgical medical device industry chain, actively expand into the synthetic biology field, and enhance the company's overall strength, which is expected to have a positive impact on future business development and operating performance